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Background. Growing evidence suggests that the Arg16Arg genotype of the beta-2 adrenergic receptor gene may be
associated with adverse effects of beta-agonist therapy. We sought to examine the association of beta-agonist use and the
Arg16Gly polymorphism with lung function and mortality among participants in the Atherosclerosis Risk in Communities
study. Methodology and Principal Findings. We genotyped study participants and analyzed the association of the Arg16Gly
polymorphism and beta-agonist use with lung function at baseline and clinical examination three years later and with all-cause
mortality during 10 years of follow-up. Lung function was characterized by percent-predicted forced expiratory volume in
1 second. Associations were examined separately for blacks and whites. Black beta-agonist users with the Arg/Arg genotype
had better lung function at baseline and at the second clinical visit than those with Arg/Gly and Gly/Gly genotypes. Adjusted
mean percent-predicted FEV1 was 21% higher in Arg/Arg subjects compared to Gly/Gly at baseline (p = 0.01) and 20% higher
than Gly/Gly at visit 2 (p = 0.01). Arg/Gly subjects had adjusted percent-predicted FEV1 17% lower than Arg/Arg at baseline but
were similar to Arg/Arg subjects at visit 2. Although black beta-agonist users with the Arg/Arg genotype appeared to have
better crude survival rates, the association between genotype and all-cause mortality was inconclusive. We found no
difference in lung function or mortality by genotype among blacks who did not use beta-agonists or among whites, regardless
of beta-agonist use. Conclusions. Black beta-agonist users with the ADRB2 Arg16Arg genotype had better lung function, and,
possibly, better overall survival compared to black beta-agonist users with the Gly16Gly genotype. Our findings highlight the
need for additional studies of sufficient size and statistical power to allow examination of outcomes among beta-agonist users
of different races and genotypes.
Citation: Ferdinands JM, Mannino DM, Gwinn ML, Bray MS (2007) ADRB2 Arg16Gly Polymorphism, Lung Function, and Mortality: Results from the
Atherosclerosis Risk in Communities Study. PLoS ONE 2(3): e289. doi:10.1371/journal.pone.0000289
INTRODUCTION
Asthma is an important cause of morbidity and mortality in the
United States, where African-Americans bear a disproportionate
burden of asthma hospitalization and have asthma mortality rates
3 to 4 times higher than whites[1]. The reasons for this disparity
are unclear but are thought to be related to poorer access to health
care, living in an urban environment, or other unknown factors
[2].
Beta-agonist medications are a mainstay of asthma treatment
and are clearly important for symptom control. Some studies,
however, have implicated heavy beta-agonist use in fatal asthma
exacerbations, although this association remains controversial [3–
5]. In 2003, a large clinical trial of the long-acting beta-agonist
salmeterol was halted after a greater-than-expected number of
asthma fatalities in the treatment arm; this increase in mortality
was statistically significant among black but not white study
participants [6].
Agonist-induced activation of the ß2-adrenergic receptor (ß2AR)
causes the dilatation of airway smooth muscle responsible for the
therapeutic effect of beta-agonist medications[7]. The Arg16Gly
polymorphism of the ß2AR gene (ADRB2) is a genetic variant
associated with receptor down-regulation, and growing evidence
suggests that it plays an important role in beta-agonist response
[8,9]. Recent studies, including a randomized clinical trial,
indicate that asthma patients with the Arg/Arg genotype may
experience adverse effects from beta-agonist use, including deter-
ioration of lung function [10–16], and recent literature reviews
suggest an emerging consensus that the Arg16 allele is associated
with clinically significant, unsatisfactory response to beta-agonists
[17–21]. Frequency of the Arg16 allele is about 39% to 42% in
whites and about 49% in blacks [22,23].
We sought to describe the association of beta-agonist use and
the ADRB2 Arg16Gly polymorphism with lung function and
mortality among participants in the Atherosclerosis Risk in
Communities (ARIC) study [24], and to examine if these
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associations vary by race. Our analysis considered factors for
which data were available from the ARIC database, including
smoking history, asthma history, respiratory symptoms, body mass
index (BMI), and use of other respiratory medications. To our
knowledge, this is the first large, population-based study to
examine the association between ADRB2 Arg16Gly polymor-
phism, lung function, beta-agonist use, and mortality.
METHODS
Subjects
The ARIC cohort consists of 15,792 adults selected by probability
sampling from four US communities [24]. At baseline clinical
examination in 1987–1989 and follow-up examination 3 years
later (‘‘visit 2’’), participants underwent pulmonary function testing
and provided information on respiratory symptoms and diagnoses,
BMI, smoking history, and medication use. Follow-up through
1998 was available for this analysis. Analysis was limited to black
and white ARIC participants who had baseline demographic data,
pulmonary function testing, smoking history, and ADRB2
Arg16Gly genotype.
Variable Definition
Subjects were classified as beta-agonist users at baseline or visit 2 if
they reported use of inhaled beta-agonists in the 2 weeks prior to
the baseline exam or 2 weeks prior to the clinical follow-up exam,
respectively. Subjects were classified as users of other respiratory
medications if they reported use of inhaled corticosteroids,
theophylline, oral steroids, or other respiratory medications in
the same time frames.
Measures of lung function were forced expiratory volume in
1 second (FEV1) and FEV1/FVC ratio. Spirometry was conducted
using a volume displacement, water-sealed spirometer. At least
three acceptable spirograms were obtained from a minimum of
five forced expirations. The best single spirogram was identified by
computer and confirmed by a technician. Quality assurance was
provided by the ARIC Pulmonary Function Center, and the
procedures followed contemporary American Thoracic Society
guidelines. We used prediction equations derived from NHANES
to estimate percent-predicted FEV1 [25]. As detailed in the on-line
supplement (Text S1), subjects were assigned a baseline respiratory
symptom score of 0 to 9 based on number of affirmative responses
to 9 respiratory symptom questions. Severity of obstructive lung
disease was classified per criteria of the Global Initiative for
Chronic Obstructive Lung Disease (GOLD) [26] and collapsed
into an indicator variable defined as GOLD Stage II or more
severe (equivalent to percent-predicted FEV1,80% and FEV1/
FVC,70%).
Respondents with affirmative responses to ‘‘Have you ever
smoked cigarettes?’’ and ‘‘Do you now smoke cigarettes?’’ were
classified as ‘‘ever smokers’’ and ‘‘current smokers,’’ respectively.
BMI was calculated as weight divided by height squared (kg/m2)
[27]. Education level was less than high school, completion of high
school, or more than high school.
Genotyping
Genotyping of the ADRB2 Arg16Gly polymorphism was per-
formed using the TaqMan assay (Applied Biosystems, Foster City,
Calif.). A 121-bp product was amplified using 0.9 mM each of the
forward primer 59-CGGCAGCGCCTTCTTG-39 and the reverse
primer 59-GGCCAGGACGATGAGAGACA-39, 50 ng DNA,
5.0 mM MgCl2, and 16TaqMan Universal PCR Master Mix
containing AmpliTaq Gold DNA Polymerase in a 22-ml reaction
volume. After an initial step of 2 minutes at 50uC and 10 minutes
at 95uC to activate the AmpliTaq Gold, products were amplified
using 40 cycles of 15 seconds at 95uC and 1 minute at 62uC. A
total of 0.2 mM of each of the sequence-specific probes 59-6FAM-
CTGGCACCCAATAGAAGCCATGC-TAMRA-39 and 59-
VIC-CTGGC ACCCAATGGAAGCCATG-TAMRA-39 was
used in the allele discrimination assay. Allele detection and
genotype calling were performed using the ABI 7900 and the
Sequence Detection System software (Applied Biosystems).
Analysis
Cross-sectional univariate and multivariate linear regression were
used to examine the association between lung function and geno-
type, stratified by beta-agonist use and race and controlling for
age, sex, smoking status, respiratory symptom score, and use of
other respiratory medications.
Crude differences in survival by genotype were examined with
the Kaplan-Meier estimator stratified by race and beta-agonist
use, tested with the log-rank statistic. Cox proportional hazards
Table 1. Demographic, phenotypic, and genotypic
characteristics by race*
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Black White All
Subjects Subjects Subjects
n = 4016 n= 10,918 n= 14,934
Age in years, mean6SD{ 53.565.8 54.465.7 54.165.8
Sex, n (%){
Male 1534 (38) 5163 (47) 6697 (45)
Female 2482 (62) 5755 (53) 8237 (55)
Cigarette smoking, n (%){
Current 1259 (32) 2995 (27) 4254 (28)
Former 952 (24) 3857 (35) 4809 (32)
Never 1801 (45) 4060 (37) 5861 (39)
Percent-predicted FEV1, mean6SD{ 95.6617.8 92.6616.7 93.4617.1
FEV1/FVC ratio, mean6SD{ 0.7660.08 0.7460.08 0.7460.08
Respiratory symptom score (0–9){
Mean 0.8 1.0 0.9
Median (interquartile range) 0 (0–1) 0 (0–1) 0 (0–1)
ADRB2 Arg16Gly genotype, n (%){
Arginine/Arginine 971 (24) 1449 (13) 2420 (16)
Arginine/Glycine 1977 (49) 5204 (48) 7181 (48)
Glycine/Glycine 1068 (27) 4265 (39) 5333 (36)
Beta-agonist use, n (%)
At baseline (visit 1) 63 (1.6) 189 (1.7) 252 (1.7)
At clinical follow-up exam (visit 2) 69 (1.7) 245 (2.2) 314 (2.1)
At visits 1 and 2 33 (0.8) 123 (1.1) 156 (1.0)
Obstructive lung disease at baseline (GOLD Stage II or worse)**{
Yes 658 (16) 2657 (24) 3315 (22)
No 3354 (84) 8258 (76) 11612 (78)
*FEV1 denotes forced expiratory volume in 1 second, FVC forced vital capacity,
SD standard deviation, ADRB2 beta2 adrenergic receptor gene
**GOLD Stage II obstructive lung disease defined as percent-predicted
FEV1,80% and FEV1/FVC,70% based on criteria from the Global Initiative for
Chronic Obstructive Lung Disease [26]
{p,0.05 for test of difference across race using x2 test of heterogeneity for Rx2
contingency table for categorical variables or ANOVA F test for continuous
variables, transformed as needed
doi:10.1371/journal.pone.0000289.t001..
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models stratified by race and beta-agonist use were used to
estimate hazard ratios by genotype, controlling for age, sex,
FEV1/FVC ratio, respiratory symptom score, and smoking status.
Analyses were conducted with SASv9 (Cary, NC).
RESULTS
Of 15,552 eligible subjects, 567 (3.4%) were excluded because they
did not consent to genotyping or genotyping was unsuccessful. Of
the remaining subjects, 46 lacked pulmonary function data and 5
lacked smoking history, leaving 14,934 subjects for analysis. Of
these, 4016 (27%) were black. Subject characteristics are summar-
ized in Table 1. Subjects had a mean age of 54 years at baseline
and 55% were female. Overall, 1.7%, 2.1%, and 1% of subjects
reported beta-agonist use at baseline, visit 2, and both visits,
respectively. Black subjects were slightly younger, had better
baseline lung function, and were less likely to suffer from obstruc-
tive lung disease; in addition, they were more likely to be female
and never smokers (p,0.01 for all).
ADRB2 Arg16Gly genotype frequencies varied by race
(p,0.01), with 49% Arg/Gly, 27% Gly/Gly, and 24% Arg/Arg
among blacks and 48% Arg/Gly, 39% Gly/Gly, and 13% Arg/
Arg among whites. Arg16 allele frequencies were 0.49 and 0.37
among blacks and whites, respectively, and were consistent with
Hardy-Weinberg equilibrium within each race. Overall, genotype
frequencies did not differ by age or sex, and genotype was not
associated with obstructive lung disease. Subjects with the Arg/
Arg genotype were more likely to be never smokers (p = 0.01).
Characteristics of subjects reporting beta agonist use at baseline
are provided in Table 2. Among black beta-agonist users, percent-
predicted FEV1 and respiratory symptom score varied by
genotype, with Arg/Arg subjects having better lung function and
fewer symptoms, as described below (p = 0.01 and p=0.02,
respectively). Among white beta-agonist users, only smoking status
varied by genotype, with Arg/Arg subjects more likely to be never
smokers (p = 0.03). Black beta-agonist users with Arg/Arg were
also more likely to be never smokers but this association was not
statistically significant.
Among black subjects with beta-agonist use at baseline (n = 63),
those with the Arg/Arg genotype had better baseline lung function
than those with Arg/Gly or Gly/Gly genotypes [crude percent-
predicted FEV1 87% (95% CI 69% to 105%) for Arg/Arg, 66%
(95% CI 60% to 73%) for Arg/Gly, and 63% (95% CI 55% to
70%) for Gly/Gly, p= 0.01 for trend, Fig. 1]. Results were similar
in a model controlling for age, sex, smoking status, respiratory
symptom score, and use of other respiratory medication, in which
adjusted mean percent-predicted FEV1 was 21% higher in Arg/
Arg subjects compared to Gly/Gly (p = 0.01). We obtained
a qualitatively similar result using the endpoint of baseline
FEV1/FVC ratio, although the relationship was not statistically
significant. We found no difference in lung function by genotype
among white subjects with beta-agonist use at baseline and among
non-users of beta-agonists of either race. Crude and adjusted lung
function estimates by race and genotype, stratified by beta-agonist
use, are summarized in Table 3.
Black beta-agonist users with the Arg/Arg genotype reported
slightly fewer respiratory symptoms at baseline than those with
Arg/Gly and Gly/Gly (median of 4 symptoms for Arg/Arg versus
5 symptoms for Arg/Gly and Gly/Gly, p = 0.02). Black beta-
agonist users with the Gly/Gly genotype were more likely to report
taking inhaled corticosteroids at baseline (24% vs 6% for Arg/Gly
Table 2. Characteristics of subjects reporting beta-agonist use at baseline by race and ADRB2 Arg16Gly genotype
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Black beta-agonist users White beta-agonist users
Arg/Arg Arg/Gly Gly/Gly Arg/Arg Arg/Gly Gly/Gly
n = 11 n= 35 n= 17 n= 27 n =88 n =74
Age in years, mean6SD 54.464.7 54.366.2 55.566.0 55.065.9 57.165.9 56.166.0
Sex, n (%)
Male 2 (18) 12 (34) 4 (24) 10 (37) 49 (56) 34 (46)
Female 9 (82) 23 (66) 13(76) 17 (63) 39 (44) 40 (54)
Cigarette smoking, n (%) {whites only
Current 1 (9) 8 (23) 5 (29) 5 (19) 28 (32) 24 (32)
Former 3 (27) 13 (37) 8 (24) 8 (30) 42 (48) 27 (36)
Never 7 (64) 14 (40) 14 (47) 14 (52) 18 (20) 23 (31)
Percent-predicted FEV1, mean6SD {blacks only 87631 66621 63615 67627 63624 65627
FEV1/FVC ratio mean6SD 0.7060.14 0.6260.13 0.6160.11 0.6060.14 0.5860.13 0.5960.16
Respiratory symptom score (0–9), mean {blacks only 3.9 5.2 4.6 5.8 5.1 5.2
Median (IQR) 4 (0–7) 5 (4–6) 5 (3–6) 6 (4–8) 5(3.5–9) 5 (3–8)
Obstructive lung disease at baseline (GOLD Stage.= 2)*
Yes 5 (45) 26 (74) 13 (76) 22 (81) 75 (85) 53 (72)
No 6 (55) 9 (26) 4 (24) 5 (19) 13 (15) 21 (28)
Inhaled corticosteroid use at baseline, n (%)
Yes 1 (9) 2 (6) 4 (24) 4 (15) 8 (9) 10 (14)
No 10 (91) 22 (94) 13 (76) 23 (85) 80 (91) 64 (86)
*GOLD Stage II obstructive lung disease defined as percent-predicted FEV1,80% and FEV1/FVC,70% based on criteria from the Global Initiative for Chronic Obstructive
Lung Disease [26]
{p,0.05 for test of difference across genotype using x2 test of heterogeneity for Rx2 contingency table for categorical variables or ANOVA F test for continuous
variables, transformed as needed
doi:10.1371/journal.pone.0000289.t002..
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and 9% for Arg/Arg), although this difference was not statistically
significant (p = 0.15).
A similar relationship was observed among black subjects
reporting beta-agonist use at visit 2 (n = 69, 62 of whom provided
pulmonary function data). Those with the Arg/Arg genotype had
percent-predicted FEV1 that was, on average, 20% higher than
those with the Gly/Gly genotype, controlling for the same vari-
ables as above (p = 0.01). However, at visit 2, heterozygotes had
lung function levels similar to those with the Arg/Arg genotype.
No differences in lung function by genotype were observed in
whites reporting beta-agonist use at baseline (n = 189) or at visit 2
(n = 231). Because only 31 black subjects reported beta-agonist use
at both visits, there were too few subjects with each genotype to
assess temporal variation in pulmonary function by genotype and
race.
Subjects were followed for an average of 9.9 years. Number of
deaths and average length of follow-up by race and genotype,
stratified by baseline beta-agonist use, are presented in Table 4.
Among black subjects using beta-agonists at baseline, 18% of those
with Arg/Arg died during follow-up compared with 29% of those
with Arg/Gly and 41% of subjects with Gly/Gly (25th percentile
survival time of.10 years for Arg/Arg, 9.0 years for Arg/Gly,
and 5.5 years for Gly/Gly). This difference in crude mortality
rates by genotype (Fig. 2) was not statistically significant (p = 0.33).
Among white subjects reporting beta-agonist use at baseline, 22%
of those with Arg/Arg died during follow-up compared to 25%
with Arg/Gly and 27% with Gly/Gly (p= 0.27). We found no
evidence of a difference in survival rates by genotype among blacks
or whites who did not use beta-agonists. Controlling for age, sex,
baseline FEV1/FVC ratio, baseline respiratory symptom score,
and baseline smoking status, blacks using beta-agonists at baseline
with the Arg/Gly genotype had better survival than black beta-
agonist users with other genotypes [hazard ratio of 2.5 for Arg/
Arg compared to Arg/Gly and 5.4 for Gly/Gly compared to Arg/
Gly, p= 0.04]. Crude and adjusted hazard ratios by race and beta-
agonist use are presented in Table 5.
A similar pattern in crude survival rates was seen among black
subjects reporting beta-agonist use at visit 2 (n = 69), with those
with the Arg/Arg genotype having better crude survival (25th
percentile survival of greater than 10 years for Arg/Arg, 8.8 years
for Arg/Gly, and 7.9 years for Gly/Gly, p = 0.24). After control-
ling for age, sex, FEV1/FVC ratio at visit 2, respiratory symptoms
at visit 2, and smoking status at visit 2, those with Arg/Arg had
better survival than black beta-agonist users with other genotypes
(adjusted hazard ratio 8.0 for Arg/Gly compared to Arg/Arg and
13.8 for Gly/Gly compared to Arg/Arg, p = 0.02). This pattern is
inconsistent with that seen among blacks with baseline beta-
agonist use, among whom those with the Arg/Gly genotype
appeared to have better adjusted survival.
Among white subjects reporting beta-agonist use at visit 2, 21%
of those with Arg/Arg died during follow-up compared to 20%
with Arg/Gly and 18% with Gly/Gly (p = 0.88). We observed no
differences in survival by genotype among black or white subjects
not reporting beta-agonist use at visit 2.
DISCUSSION
To our knowledge, this is the first large, population-based study to
examine the association between ADRB2 Arg16Gly polymor-
phism, beta-agonist use, lung function, and mortality. We found
better lung function among black beta-agonist users with the Arg/
Arg genotype compared with the Arg/Gly and Gly/Gly geno-
types. These findings were not seen among blacks who did not use
beta-agonists or among whites regardless of beta-agonist use.
Our finding of better lung function among black beta-agonist
users with the Arg/Arg genotype is at odds with results from other
studies that found regular beta-agonist use associated with reduced
peak flow rates [12] and more frequent exacerbations in asthma-
tics with an Arg16 allele [28] as well as a recent randomized
clinical trial [10] that found that regular beta-agonist use produced
an improvement in lung function among Gly/Gly subjects but
a deterioration in lung function among Arg/Arg subjects.
Unfortunately, the number of beta-agonist users in our study is
too small to permit analysis of temporal changes in lung function
by genotype and race.
A possible explanation for the positive association we observed
between Arg/Arg and pulmonary function among black beta-
agonist users is that the Arg/Arg genotype is associated with less
severe respiratory disease. Black beta-agonist users with the Arg/
Arg genotype had lower median respiratory symptom scores and
were less likely to have obstructive lung disease and to use inhaled
corticosteroids compared to other genotypes. These features were
similar across genotypes among white beta-agonist users. Thus, we
cannot rule out the possibility that our findings are related to black
beta-agonist users with the Arg/Arg genotype having less severe
respiratory disease (and requiring less beta-agonist medication).
Figure 1. Baseline percent-predicted forced expiratory volume in
1 second (FEV1) by ADRB2 Arg16Gly genotype, stratified by beta-
agonist use in blacks (upper panel, p = 0.01) and whites (lower panel,
p = 0.77)
doi:10.1371/journal.pone.0000289.g001
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Furthermore, both black subjects and those with the Arg/Arg
genotype were more likely to be never smokers. Although we
attempted to control for this difference by including baseline
smoking status in the regression models, residual confounding by
smoking status cannot be excluded.
Our findings regarding the association between ADRB2
Arg16Gly polymorphism, beta-agonist use, and all-cause mortality
are inconclusive. Data from the baseline clinical visit suggest black
beta-agonist users with the Arg/Gly genotype have better survival,
whereas data from the second clinical visit suggest that black beta-
agonist users with the Arg/Arg genotype have better survival. This
fluctuation may be due to the small numbers of black beta-agonist
users with each genotype. However, the results are consistent in
that both suggest that black beta-agonist users with an Arg16 allele
may have lower all-cause mortality than Gly/Gly homozygotes,
after controlling for important factors like age, smoking status, and
respiratory symptom score. Our mortality findings highlight the
need for additional studies of sufficient size and statistical power to
allow examination of differential mortality among beta-agonist
users of different races and genotypes.
This analysis has several limitations. Because statistical power is
limited by the small number of black beta-agonist users (n=62), we
cannot rule out the possibility that our findings are due to chance.
The small number of beta-agonist users precluded an analysis of
temporal trends to examine if outcomes improved over time.
Medication use was self reported and limited to the two-week period
Table 3. Crude and adjusted baseline lung function by race and ADRB2 Arg16Gly genotype for subjects with (top) and
without (bottom) baseline beta-agonist use
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Blacks with baseline beta-agonist use Whites with baselinebeta-agonist use
Arg/Arg Arg/Gly Gly/Gly Arg/Arg Arg/Gly Gly/Gly
n = 11 n= 35 n= 17 n=27 n= 88 n= 74
Crude percent-predicted FEV1, mean (95%CI) 87 (69–105) 66 (60–73) 63 (55–70) 67 (57–77) 63 (58–68) 65 (59–71)
Adjusted percent-predicted FEV1, mean (95%CI) 83 (70–97) 67 (60–74) 63 (53–73) 61 (53–69) 66 (61–70) 65 (60–69)
Crude FEV1/FVC ratio, mean (95%CI) 0.70 (0.61–0.78) 0.62 (0.58–0.67) 0.61 (0.55–0.66) 0.60 (0.55–0.65) 0.58 (0.55–0.61) 0.59 (0.56–0.63)
Adjusted FEV1/FVC ratio, mean (95%CI) 0.69 (0.61–0.76) 0.63 (0.59–0.67) 0.61 (0.55–0.66) 0.57 (0.52–0.61) 0.59 (0.57–0.62) 0.59 (0.56–0.62)
Blacks without baseline beta-agonist user Whites without baseline beta-agonist user
Arg/Arg Arg/Gly Gly/Gly Arg/Arg Arg/Gly Gly/Gly
n = 960 n= 1942 n= 1051 n=1422 n= 5116 n= 4191
Crude percent-predicted FEV1, mean (95%CI) 96 (95–97) 96 (95–97) 96 (95–98) 93 (92–94) 93 (93–94) 93 (93–94)
Adjusted percent-predicted FEV1, mean (95%CI) 96 (95–98) 96 (95–96) 96 (95–97) 93 (92–94) 93 (93–93) 93 (93–94)
Crude FEV1/FVC ratio, mean (95%CI) 0.77 (0.76–0.77) 0.77 (0.76–0.77) 0.77 (0.76–0.77) 0.74 (0.74–0.74) 0.74 (0.74–0.74) 0.74 (0.74–0.74)
Adjusted FEV1/FVC ratio, mean (95%CI) 0.77 (0.76–0.77) 0.77 (0.76–0.77) 0.77 (0.76–0.77) 0.74 (0.74–0.74) 0.74 (0.74–0.74) 0.74 (0.74–0.74)
*Adjusted for age, sex, baseline smoking status, respiratory symptom score, and use of other respiratory medication
doi:10.1371/journal.pone.0000289.t003..
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Table 4. Number of deaths and average length of follow-up by race and genotype for subjects with (top) and without
(bottom) baseline beta-agonist use
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Blacks with baseline beta-agonist use Whites with baseline beta-agonist use
Arg/Arg Arg/Gly Gly/Gly Arg/Arg Arg/Gly Gly/Gly
n = 11 n=35 n= 17 n= 27 n =88 n= 74
Number (%) of deaths 2 (18%) 10 (29%) 7 (41%) 6 (22%) 22 (25%) 20 (27%)
Mean person-years of follow-up 9.3 9.1 8.2 9.4 9.3 9.1
Blacks without baseline beta-agonist user Whites without baseline beta-agonist user
Arg/Arg Arg/Gly Gly/Gly Arg/Arg Arg/Gly Gly/Gly
n = 960 n=1942 n= 1051 n= 1422 n =5116 n= 4191
Number (%) of deaths 119 (12%) 242 (13%) 142 (14%) 112 (8%) 354 (7%) 315 (8%)
Mean person-years of follow-up 9.7 9.7 9.6 10.0 10.1 10.1
doi:10.1371/journal.pone.0000289.t004..
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prior to each clinic visit. We had no data on haplotypes that have
been described in relation to response to beta-agonists, such as
haplotypes including the ADRB2 Gln27Glu polymorphism [29].
Our results among black beta-agonist users may not be generalizable
if the pattern of genetic variation in the black subsample of our study
population differs in significant ways from other black populations.
In summary, we observed that black beta-agonist users with the
Arg/Arg genotype at codon 16 of the ADRB2 had better lung
function, and, possibly, better overall survival compared to black
beta-agonist users with the Gly/Gly genotype. Why we observe an
association of the Arg/Arg genotype with outcomes among black
but not white beta-agonist users is unclear and could be due to
differential severity of respiratory disease, underlying differences in
response to beta-agonist medication, or chance. Response to beta-
agonists is undoubtedly a complex process influenced by many
genes, and it is possible that associations seen with the Arg16Gly
polymorphism are due to linkage disequilibrium with other
polymorphisms whose prevalence differs by race (summarized in
supplemental table S1). Additional studies with sufficient statistical
power to detect differences between races will be critically
important to improve understanding of this potentially important
association.
SUPPORTING INFORMATION
Table S1 Measures of linkage disequilibrium between ADRB2
Arg16Gly (rs1042713) and Gln27Glu (rs1042714) polymorphisms
by race/ethnicity
Figure 2. Crude survival among black (upper panel, n = 63, p = 0.33) and white (lower panel, n = 189, p = 0.27) study participants reporting baseline
beta-agonist use by ADRB2 Arg16Gly genotype
doi:10.1371/journal.pone.0000289.g002
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Found at: doi:10.1371/journal.pone.0000289.s001 (0.05 MB
DOC)
Text S1 Derivation of respiratory symptom score
Found at: doi:10.1371/journal.pone.0000289.s002 (0.03 MB
DOC)
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